Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

More CRISPR Stock Catalysts Ahead

TheMotleyFool

0 0

Gene-editing stocks took a big step forward in November when CRISPR Therapeutics (NASDAQ: CRSP) reported fairly positive results from the first patients treated with a CRISPR-based drug. Early success from the present leader in the field also pushed up shares of Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA), even though neither has reported any clinical-trial results yet.

If you missed out on the latest big catalyst that drove all three CRISPR stocks higher, don't worry -- you'll get more chances soon. Here's what you need to know about the road ahead for CRISPR, Editas, and Intellia.

Image source: Getty Images.

Source Fool.com

Like: 0

CRSP

Share